A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium

Multidrug-resistant tuberculosis (MDR-TB), defined as TB caused by Mycobacterium tuberculosis strains resistant to isoniazid and rifampicin (the core anti-TB drugs currently in use), and extensively drug resistant tuberculosis (XDR-TB), defined as MDR-TB caused by strains resistant to at least one fluoroquinolone and one injectable second-line anti-TB drug in addition to isoniazid and rifampicin, has attracted interest at different levels (1-5).